LadRx (LADX)
OTHER OTC:LADX
Top Page
No summary available
Positive Factors
Proprietary Technology Platforms
LadRx's focus on proprietary technology platforms provides a competitive edge in developing unique cancer therapeutics, potentially leading to successful commercialization and partnerships.
Negative Factors
Negative Equity
Negative equity suggests that LadRx is facing financial distress, which could hinder its ability to invest in R&D and commercialize its drug candidates effectively.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Technology Platforms
LadRx's focus on proprietary technology platforms provides a competitive edge in developing unique cancer therapeutics, potentially leading to successful commercialization and partnerships.
Read all positive factors
LadRx (LADX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.25K
Dividend YieldN/A
Average Volume (3M)1.01K
Price to Earnings (P/E)―
Beta (1Y)-13.18
Revenue GrowthN/A
EPS Growth-246.39%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.21
Shares Outstanding495,092
10 Day Avg. Volume91
30 Day Avg. Volume1,007
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.59
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-7.20
Enterprise Value/Revenue-26.25
Enterprise Value/Gross Profit-707.00
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)204
Revenue Forecast (FY)$113.28M
LadRx Business Overview & Revenue Model
Company Description
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti...
How the Company Makes Money
LadRx makes money primarily through the development and commercialization of its proprietary cancer therapeutics. The company generates revenue through licensing agreements, partnerships with larger pharmaceutical companies, and potential sales of...
LadRx Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 257.00 | -5.71K | -11.84K | -15.00K | -13.98K | -29.04K |
| EBITDA | -3.51M | -1.58M | -3.81M | -4.19M | -13.16M | -6.80M |
| Net Income | -2.50M | -1.59B | 400.44K | -4.20M | -13.18M | -6.70M |
Balance Sheet | ||||||
| Total Assets | 260.07K | 839.51K | 2.31M | 2.25M | 8.73M | 12.06M |
| Cash, Cash Equivalents and Short-Term Investments | 206.95K | 759.74K | 2.07M | 1.37M | 6.77M | 10.00M |
| Total Debt | 0.00 | 0.00 | 33.61K | 229.61K | 415.20K | 596.30K |
| Total Liabilities | 2.39M | 2.26M | 2.20M | 2.22M | 3.95M | 3.19M |
| Stockholders Equity | -2.13M | -1.42M | 107.35K | 25.72K | 4.78M | 8.87M |
Cash Flow | ||||||
| Free Cash Flow | -1.86B | -1.31B | 1.01M | -4.83M | -12.32M | -6.17M |
| Operating Cash Flow | -1.86B | -1.31B | 1.01M | -4.83M | -12.31M | -6.14M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -766.00 | -7.00K | -25.90K |
| Financing Cash Flow | 0.00 | 0.00 | -318.81K | -561.38K | 9.08M | 39.00K |
LadRx Technical Analysis
Neutral
0.05
Price Trends
0.07
Negative
0.11
Negative
0.70
Negative
Market Momentum
>-0.01
Negative
45.24
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LADX, the sentiment is Neutral. The current price of 0.05 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.07, and below the 200-day MA of 0.70, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.24 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LADX.
LadRx Risk Analysis
LadRx disclosed 38 risk factors in its most recent earnings report. LadRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LadRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $25.25K | -0.01 | ― | ― | ― | -246.39% | |
44 Neutral | $2.12M | -0.24 | ― | ― | 178.82% | -4121.10% | |
43 Neutral | $1.75M | -0.07 | -63.03% | ― | -100.00% | 86.75% | |
| ― | $2.54M | -0.17 | -168.95% | ― | ― | 90.27% |
* Healthcare Sector Average
LADX
LadRx
0.05
-1.23
-96.02%
BDRX
Biodexa Pharmaceuticals
3.87
-78.63
-95.31%
QCLS
Q/C Technologies
3.51
-33.01
-90.39%
SCNI
Scinai Immunotherapeutics
0.61
-2.05
-77.07%
OGEN
Oragenics
0.58
-4.64
-88.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―